StreetInsider.com News Articles

Foghorn Therapeutics (FHTX) Reiterated at Buy by Stifel Amid Early Pipeline Excitement

Mon, 17 Aug 2026 07:10:30 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $12.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).

The analyst commented, "Our $12 target price values FHTX at ~3.1x EV/5-yr forward sales (2031E). This is a large premium to FHTX’s small/mid-cap peer group (~0.4x/~2.0x), which we believe is justified given the favorable partnership with LLY to co-develop FHD-909, impressive first-in-class/whollyowned degrader pipeline, and cash runway into 1H28 (beyond major de-risking catalysts). FHTX has a unique integrated, scalable platform to systematically drug the complex machinery of gene expression in cancer. We believe the FHTX platform drives significant value (LLY’s investment/collaboration is a testament

Foghorn Therapeutics Inc. (FHTX) Tops Q2 EPS by 15c

Thu, 06 Aug 2026 08:02:34 -0400

Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.

Form 10-Q Foghorn Therapeutics For: Jun 30

Thu, 06 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26878464.html

Form 10-Q Foghorn Therapeutics For: Jun 30

Thu, 06 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26878464.html

Form 8-K Foghorn Therapeutics For: Aug 06

Thu, 06 Aug 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26878432.html

Form 8-K Foghorn Therapeutics For: Aug 06

Thu, 06 Aug 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26878432.html

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

Thu, 06 Aug 2026 07:00:00 -0400

- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population

- Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027

- Accelerating a novel oral small molecule in immunology and inflammation toward IND in 2027

- Strong balance sheet with cash, cash equivalents, and marketable securities of approximately
$168 million; cash runway into the first half of 2028

WATERTOWN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) --

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

Thu, 06 Aug 2026 07:00:00 -0400

- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population

- Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027

- Accelerating a novel oral small molecule in immunology and inflammation toward IND in 2027

- Strong balance sheet with cash, cash equivalents, and marketable securities of approximately
$168 million; cash runway into the first half of 2028

WATERTOWN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) --

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director

Wed, 01 Jul 2026 07:00:00 -0400

Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncology
His appointment will strengthen Step Pharma’s board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours.

Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Neil J. Gallagher, MD, PhD, as Non-Executive Director effective immediately. He will support the Company as it continues to advance its first-in-class CTPS1

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director

Wed, 01 Jul 2026 07:00:00 -0400

Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncology
His appointment will strengthen Step Pharma’s board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours.

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Lynch Thomas J. Jr.

Thu, 25 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260625/26692342.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Lynch Thomas J. Jr.

Thu, 25 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260625/26692342.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Duty Stuart

Thu, 25 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260625/26692323.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Duty Stuart

Thu, 25 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260625/26692323.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Biller Scott

Thu, 25 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260625/26692281.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Biller Scott

Thu, 25 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260625/26692281.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Mendelsohn Michael

Thu, 25 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260625/26692244.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Mendelsohn Michael

Thu, 25 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260625/26692244.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Gallagher Neil

Thu, 25 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260625/26692254.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Gallagher Neil

Thu, 25 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260625/26692254.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: SMITH IAN F

Thu, 25 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260625/26692235.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: SMITH IAN F

Thu, 25 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260625/26692235.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: GILL SIMBA

Thu, 25 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260625/26692215.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: GILL SIMBA

Thu, 25 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260625/26692215.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Cole Douglas G.

Thu, 25 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26692190.html